GlassScriptPhysician profile
Moe M Mya
NPI 1104930502
$2,186.81
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $562 · 2021: $721.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $515.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $274.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $160.82 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.03 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $115.00 | 2021 | |
| Amarin Pharma, INC. | $109.70 | 2019-2021 | |
| Glaxosmithkline, LLC. | $104.36 | 2019-2020 | |
| Pfizer INC. | $87.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $83.28 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $72.28 | 2019 | |
| Amgen INC. | $70.61 | 2019-2020 | |
| Lilly USA, LLC | $67.48 | 2019-2021 | |
| Esperion Therapeutics, INC. | $62.99 | 2020-2021 | |
| Abbvie INC. | $58.96 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.21 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.32 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.70 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $36.13 | 2021 | |
| Daiichi Sankyo INC. | $18.91 | 2021 | |
| Astellas Pharma US INC | $15.77 | 2019 | |
| Eisai INC. | $13.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.52 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moe Mya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.